Sudanese Female Activist Wins Martin Institute Prize for Human Rights Defenders

Tahani Abbas holds the Martin Institute Prize (Martin Institute)
Tahani Abbas holds the Martin Institute Prize (Martin Institute)
TT

Sudanese Female Activist Wins Martin Institute Prize for Human Rights Defenders

Tahani Abbas holds the Martin Institute Prize (Martin Institute)
Tahani Abbas holds the Martin Institute Prize (Martin Institute)

Tahani Abbas, a Sudanese human rights activist, was awarded the Martin Institute Prize in Switzerland. This is the fifth edition of the prize awarded to human rights defenders and was awarded to her in appreciation of her work on human rights and women's issues in Sudan.

The Martine Institute Prize is named after a French-Swiss woman who dedicated her life to defending human rights. After her death, her family and the Swiss authorities dedicated a prize in her name, to be given on the 6th of March every year as part of the Human Rights Film Festival, to honor human rights activists and to remind nations of the importance of their rights.

Ms. Abbas told Asharq Al-Awsat that she was proud to receive the prize and because it embodies the distant world’s perception of the Sudanese people’s struggle and shows that the world is watching out for human rights. She went on to say that “personally, the award credits me with a strong role with regards to defending human rights and makes me feel that our efforts and positions in the defense of human rights are appreciated and did not go in vain."

In her acceptance speech, Abbas stressed that all Sudanese women qualify to stand in her place and receive the prize, adding that “I am only a miniature and symbolic example that personifies that struggle of all the women of Sudan. I am an extension of Sudan’s feminist struggle, which is deeply ingrained in its history since before the era of the Kandakes or Nubian Queens, passing through Mendi, daughter of the Sultan Ajabna, and reaching the icon of the Sudanese revolution, Alaa Salah."

Despite the admiration of observers and the organizers of the prize for the role of Sudanese women in the revolution, Abbas demonstrated her anger at what she calls “women's weak political participation of after the revolution”. However, she says “Despite being denied political participation after the success of the revolution, our struggle will not stop.”

Abbas says she is from rural Sudan, a member of the nation and of the feminist movement in particular and an activist defending human rights, saying, “I was nominated for the International Federation for Human Rights Award, it received the award for which 26 people and 16 organizations around the world had been nominated.

Abbas has been an active human rights defender since 2009 and is a member of many Sudanese feminist and human rights groups. She is a member of the executive committee of the Regional Alliance of Women Human Rights Defenders of North Africa and the Middle East, a member of the executive committee of the No to the Oppression of Sudanese Women Initiative, the My Fair Home campaign which is concerned with domestic workers, the I am Sudanese, which is concerned with nationality and a member of the Sudanese Alliance to End Child Marriage.

In her assessment of the human rights situation in Sudan after the revolution, she says that it has improved a lot as per international standards.

She said: ”The reports of international human rights organizations demonstrate this, and, locally, we feel that, as human rights defenders, we have achieved some victories."



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”